Wearable cardioverter-defibrillators in contemporary arrhythmia care
A wearable cardioverter-defibrillator (WCD) is an external system designed to detect sustained ventricular tachycardia or ventricular fibrillation and deliver an electrical shock without an implanted device. It combines an electrode garment, monitoring unit, alarms, and a treatment algorithm that gives the patient time to cancel an inappropriate shock. The technology is intended for temporary protection rather than indefinite replacement of an implantable cardioverter-defibrillator (ICD).
Its clinical role has expanded as clinicians have recognized that sudden cardiac death risk often changes rapidly. Left ventricular function may recover after myocardial infarction, revascularization, myocarditis, newly diagnosed cardiomyopathy, or optimization of guideline-directed medical therapy. During this interval, an immediate permanent ICD may be premature, while leaving a patient unprotected may be unacceptable.
The central question is therefore one of risk, timing, and practicality. Current evidence supports selective use in carefully assessed patients, but it does not justify routine prescription for every person with a transient reduction in ejection fraction. Real-world outcomes depend heavily on adherence, patient education, competing mortality, and the quality of follow-up.
Why temporary protection matters
Primary-prevention ICD implantation is commonly deferred for a period after myocardial infarction or the diagnosis of nonischemic cardiomyopathy. This waiting period allows ventricular function to improve and permits treatment to address reversible causes. Yet some patients have substantial short-term risk because of severe left ventricular dysfunction, ventricular arrhythmias, extensive myocardial injury, or an inability to receive an implanted device immediately.
A WCD can serve as a bridge during this vulnerable phase. It may also be considered when an ICD has been removed because of infection, when implantation is temporarily contraindicated, or while a patient awaits transplantation or another definitive intervention. In these settings, the device offers protection without introducing transvenous leads or requiring a surgical procedure.
The benefit is conditional rather than automatic. The system must be worn for meaningful periods, electrodes must maintain adequate contact, and the patient must respond appropriately to alarms. A prescription without a structured plan for education, technical support, reassessment, and discontinuation can produce limited clinical value.
Current clinical indications
The most established use is for patients at temporary risk of life-threatening ventricular arrhythmia who do not yet meet, or cannot yet fulfill, criteria for a permanent ICD. This includes selected individuals early after myocardial infarction with markedly reduced ejection fraction, patients with newly diagnosed cardiomyopathy during medical optimization, and people recovering from myocarditis or other potentially reversible myocardial disease.
A WCD may be reasonable after ICD explantation for infection, particularly when reimplantation must be delayed until bloodstream or pocket infection has been treated. It can also be used when a patient has a temporary contraindication to implantation, such as an active infection, or when a definitive decision is pending after electrophysiological evaluation. The indication should be documented in relation to a specific risk window and a planned review date.
Secondary-prevention situations require particular care. A survivor of ventricular fibrillation or hemodynamically unstable ventricular tachycardia generally has a strong indication for an ICD unless a fully reversible cause has been established. A WCD should not become a substitute for permanent therapy simply because implantation is inconvenient or deferred without explanation.
Patients with genetic arrhythmia syndromes, advanced heart failure, or recurrent ventricular arrhythmia may need individualized assessment. The device does not treat the underlying substrate, eliminate the need for beta-blockers or other disease-modifying therapy, or provide the comprehensive pacing functions available from some implanted systems.
What randomized and registry evidence shows
The largest randomized evaluation, the VEST trial, studied patients with recent myocardial infarction and reduced ejection fraction who were considered at risk during the period before ICD eligibility. In the intention-to-treat analysis, WCD use did not significantly reduce arrhythmic death compared with medical therapy alone. All-cause mortality was lower as a secondary outcome, but that finding requires cautious interpretation because adherence was imperfect and the trial was not powered primarily around that endpoint.
VEST also highlighted a central limitation: prescription is not equivalent to exposure. Median wear time was approximately 18 hours per day, and the risk of ventricular arrhythmia is present during the hours when the garment is removed. Per-protocol and as-treated analyses suggested greater protection among patients who wore the device consistently, although such analyses can be affected by differences between adherent and nonadherent patients.
Observational studies and registries generally report successful termination of ventricular tachyarrhythmias, low but clinically relevant rates of inappropriate shocks, and substantial variation in wear time. These studies are valuable for understanding practice outside a trial, including use after ICD extraction and in nonischemic cardiomyopathy. They are less able to establish causality because WCD recipients are selected by clinicians and often have different baseline risks from untreated comparison groups.
Evidence syntheses therefore support a targeted approach. The likely benefit is greatest when short-term arrhythmic risk is credible, the threat is temporary, the patient can reliably wear the device, and a near-term decision about recovery or ICD implantation is expected. For broader arrhythmia research journal coverage of electrophysiology and device-based care, clinicians can consult peer-reviewed studies alongside regional guidelines.
| Clinical situation | Potential role of a WCD | Essential reassessment |
|---|---|---|
| Newly diagnosed cardiomyopathy with severely reduced ejection fraction | Bridge during medical therapy and recovery assessment | Repeat imaging, symptoms, arrhythmia burden, medication tolerance |
| Early period after myocardial infarction or revascularization | Selected temporary protection when risk is judged high | Ventricular function, ischemia control, heart failure treatment |
| Recent ventricular arrhythmia with a reversible or unresolved cause | Short-term protection while cause and definitive therapy are clarified | Electrophysiology review and ICD eligibility |
| ICD extraction for infection | Protection while infection is treated and reimplantation is planned | Blood cultures, wound status, timing of reimplantation |
| Temporary contraindication to ICD implantation | Noninvasive bridge when risk remains clinically significant | Resolution of contraindication and permanent device decision |
Selecting patients in real-world practice
Patient selection should begin with an estimate of absolute short-term risk, not ejection fraction alone. Important factors include prior sustained ventricular arrhythmia, myocardial scar, syncope suspected to be arrhythmic, nonsustained ventricular tachycardia, the cause and duration of cardiomyopathy, renal function, heart failure severity, and the expected reversibility of ventricular dysfunction.
The treatment plan should specify why an ICD is not being implanted now and what event will end WCD therapy. That event might be recovery of left ventricular function, completion of infection treatment, reassessment after revascularization, or a decision that permanent implantation is appropriate. Without a defined endpoint, temporary protection can drift into indefinite use with limited clinical justification.
Shared decision-making is essential. Patients should understand that the device detects and treats selected fast ventricular rhythms but cannot guarantee survival, prevent every sudden death, or replace emergency care. They should receive clear instructions about wearing the garment during sleep and routine activity, removing it only when necessary, responding to alarms, keeping the monitoring unit charged, and contacting the clinical team after a shock or suspected arrhythmia.
The practical burden deserves explicit discussion. Skin irritation, discomfort, noise, anxiety, body-image concerns, charging requirements, and interference with work or sleep can reduce adherence. A fitting review, early telephone contact, and direct access to technical assistance may improve sustained use more effectively than simply repeating the prescription.
Monitoring effectiveness and safety
Follow-up should combine clinical review with device-generated data. Wear time, alarm events, artifact, shocks, and periods without monitoring can reveal whether the intended protection is actually present. A patient who wears the device for only a few hours daily may require renewed education, a different risk-benefit discussion, or a decision to proceed with definitive therapy.
Any shock warrants prompt assessment. The clinical team should determine whether it was appropriate, whether recurrent arrhythmia is present, and whether electrolyte disturbance, ischemia, medication toxicity, or worsening heart failure contributed. Inappropriate therapy may result from oversensing, poor electrode contact, signal artifact, or supraventricular tachycardia and should trigger technical and clinical review.
A WCD should be integrated with standard care, including evidence-based heart failure treatment, ischemia management, correction of electrolyte abnormalities, and evaluation for ablation or ICD implantation when indicated. Repeat echocardiography is often central, but imaging should be interpreted alongside symptoms, rhythm history, scar assessment, and the trajectory of medical therapy.
Clinical teams can use the current article collection to follow emerging studies on ventricular arrhythmia, device therapy, and electrophysiology. Since evidence changes across populations, local protocols should be updated when new randomized data, registries, or society recommendations become available.
Practical recommendations for clinicians
The following principles help align WCD prescribing with current evidence and real-world constraints:
- Reserve the device for a defined period of meaningful, potentially changing ventricular arrhythmic risk rather than using reduced ejection fraction as the sole criterion.
- Document the reason for deferring an ICD, the expected duration of WCD use, and the clinical or imaging milestone that will guide the next decision.
- Provide hands-on education about fitting, daily wear, alarm cancellation, charging, bathing, emergency response, and what to do after a shock.
- Review adherence and device events early, then reassess ventricular function, arrhythmia history, reversible causes, and ICD eligibility at a scheduled interval.
- Treat the WCD as a bridge within comprehensive arrhythmia care, not as a replacement for disease-modifying therapy, ablation, or permanent device implantation when those treatments are indicated.
A registry-based approach can improve accountability. Recording the original indication, prescribed duration, actual wear time, shocks, complications, and final disposition—recovery, discontinuation, ICD implantation, or death—helps institutions identify which patients benefit and where support is failing. Such data are especially useful because routine practice includes populations underrepresented in randomized trials.
Clinicians should also consider disparities in access and usability. Cost, insurance approval, health literacy, unstable housing, employment demands, and limited caregiver support may affect the feasibility of continuous wear. A technically effective device has limited value if the patient cannot maintain it or cannot obtain timely assistance.
The Journal of Arrhythmia information provides access to the publication’s scope and resources for clinicians, researchers, and trainees following developments in cardiac rhythm management. Ongoing research should prioritize patient-centered outcomes, adherence interventions, comparative effectiveness, and the subgroups most likely to gain a meaningful survival benefit.
WCD therapy is best understood as a carefully monitored interval between vulnerability and a more definitive decision. When clinicians define the risk window, engage the patient, measure actual use, and reassess promptly, the technology can occupy a useful place in modern arrhythmia practice. Explore current evidence and related educational resources through the Journal of Arrhythmia, and incorporate relevant findings into local pathways for sudden-death prevention and device decision-making.